SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

Greece approves $750M rocket deal with Elbit amid negotiations for $3.5B Israeli air-defense systems

Intel VP: “We’re just not going to accept subpar products”

Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff

Buzz

Most popular

Daily

Weekly

1

“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals

2

Nice puts Actimize up for sale at a $1.5-2 billion price tag

3

Zafran raises $60 million and doubles valuation as it chooses independence over takeover offers

4

Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ

5

Cybereason founders' 7AI raises record $130 million Series A in breakneck rise

Merck

5 stories about Merck

Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros

03.06.24|Sophie Shulman

The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.

ד״ר צחון בנטואיץ׳ מייסד משותף של קיוריס Quris AI

Pharma giant Merck expands collaboration with Quris-AI

28.09.23|Meir Orbach

This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches

מוסף שבועי 18.5.23 פרופסור גל מרקל

Israeli biotech phenom puts death knell on cancer

21.05.23|Roni Dori

At 44, Gal Markel is a biotech bulldozer. After a $95 million exit, the professor of immunology serves as the Deputy Director General of Beilinson Hospital and the Director of the Davidoff Cancer Center, and is also involved in five startups. Now he has raised around $33 million to establish the Samueli Institute, researching ways to help the immune system eradicate cancer cells

“Pharma companies need to capitalize on early-stage breakthrough innovation.”

Collaboration is key for pharmaceutical companies as they seek to make the drug development process more efficient and successful, says Larisa Amir, managing director of Merck’s R&D Center.

Larisa Amir appointed Managing Director of Merck R&D Center in Israel

Amir will be responsible for managing the center and will also focus on in-house innovation and external scouting for technologies and biotechnology capabilities in Israeli startups, academia, and hospitals